Generic drug makers are making greater efforts to disclose more information on their products after years of repeated requests from doctors and medical institutions, which want to better ascertain their quality and stability of their supplies.Ohara Pharmaceutical has been disclosing…
HOME > TRENDS
TRENDS
-
Japan Drug Makers’ Workforce Down 1.3% in FY2018 amid Spate of Voluntary Redundancies
July 4, 2019
-
Drug Makers Now Required to Boost Transparency in Exec Pay; Astellas Ups Bonus, Stock Option Ratio to 70%
July 3, 2019
-
12 Foreign Drug Makers Eke Out 1.2% Growth in Japan, but Stagnation Lingers
June 21, 2019
-
Foreign Pharmas Creating Environments to Empower Women, Making Headway for Sales Reps Too
June 18, 2019
-
Female Manager Ratios at Foreign Drug Makers Rising in Japan, 7 Out of 10 Log 20%-Plus
May 28, 2019
-
Cancer Drugs Underpin Big Pharmas’ Japan Revenue in 2018
April 25, 2019
-
Drug Makers on Hunt for “Mibyo” Biz Opportunities as Pricing Rules Get Stricter
March 5, 2019
-
Industry Workforce Dwindling as More and More Staffers Take Voluntary Retirement; Astellas Could Cut 700 Jobs
February 22, 2019
-
Rituxan Biosimilar Grabs 30% Volume Share in Just 1 Year; Sales Expected to Double in 2019
February 12, 2019
-
Drug Formulary Initiatives Moving Beyond Hospitals, Generic Makers Prepping for Regional Lists
January 30, 2019
-
Top 10 PHARMA JAPAN Stories in 2018
December 26, 2018
-
Generic Industry at Crossroads: Companies Face Pressing Need to Boost Profitability ahead of FY2020
November 28, 2018
-
Economic Benefits for Patients, Healthcare Providers Driving Biosimilar Sales Growth as Quality Worries Fade
November 15, 2018
-
Hep C Market Shrinking towards Disease Elimination in 2030
October 12, 2018
-
“Follow-On” Authorized Generics Gaining Ground in Matured Gx Markets; TS-1 Grabs 80% Share
September 4, 2018
-
Strong April-June Sales Show Market Shift to SGLT2/DPP-4 Combos
August 8, 2018
-
As Biosimilars Show Mixed Performances, Lantus Follow-On Is on a Roll
July 13, 2018
-
Japan Drug Makers Downsizing Parent Companies; Takeda Sheds Over 1,000 People in Divestitures, R&D Rejig
July 3, 2018
-
Foreign Players’ Japan Sales Hit Plateau as 11 Firms See Paltry 0.2% Rise; Pfizer, Boehringer Falter
June 20, 2018
-
Drug Maker Downsizing Shows No Sign of Stopping; Boehringer to Ax 300 Jobs, while Shionogi Sees “Tremendous Reduction” in Rep Numbers
May 31, 2018
ページ
With Novartis’ CAR-T therapy Kymriah (tisagenlecleucel) hogging the headlines for its biggest-ever price tag in Japan, many continue to perceive high-price medicines as the main culprit of strained health finances, contending that they are driving up drug spending. But, is…
The workforce in the Japanese pharmaceutical sector is getting leaner and leaner, with the latest securities reports filed by 27 drug makers showing a 1.3% fall in their headcounts in FY2018, or 888 employees. The downtrend has been continuing since…
Riding on the back of an improved regulatory environment in China, major Japanese drug makers are moving to expand their businesses in the world’s second largest pharma market. Companies are pumping up their new drug pipelines, while forging solid sales…
As Japan heralds the new imperial era of Reiwa, Eisai CEO Haruo Naito sat with Jiho to look back on…
Japan’s generic market is hitting a plateau soon. Incentive measures rolled out by the government since 2002 have driven its…
Some seven years in the making, Japan’s Ministry of Health, Labor and Welfare (MHLW) finally rolled out a cost-effectiveness assessment…
Japan will go ahead with the introduction of a cost-effectiveness assessment (CEA) scheme for drugs and medical devices in April…